These are the source articles connected to the rhythm summaries.
Johnson & Johnson (NYSE:JNJ): A Dividend Quality Standout
Source: ChartMill • Published: 2026-08-17
NeutralJohnson & Johnson passes ChartMill's Best Dividend Stocks screen with a high dividend rating, robust profitability, and solid health. A reliable income pick.
View original source →Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?
Source: Yahoo • Published: 2026-08-13
NeutralThe World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]
View original source →Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care
Source: Yahoo • Published: 2026-08-12
NeutralJohnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson’s focus on higher growth therapeutic and medtech areas that are important for its long term...